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Abstract
Background: Mortality among people with human immunodeficiency virus (HIV) infection is increasingly due to
non-communicable causes. This has been observed mostly in developed countries and the routine care of HIV
infected individuals has now expanded to include attention to cardiovascular risk factors. Cardiovascular risk factors
such as high blood pressure are often overlooked among HIV seropositive (+) individuals in sub-Saharan Africa. We
aimed to determine the effect of blood pressure on mortality among HIV+ adults in Kenya.
Methods: We performed a retrospective analysis of electronic medical records of a large HIV treatment program in
western Kenya between 2005 and 2010. All included individuals were HIV+. We excluded participants with AIDS,
who were <16 or >80 years old, or had data out of acceptable ranges. Missing data for key covariates was addressed
by inverse probability weighting. Primary outcome measures were crude mortality rate and mortality hazard ratio (HR)
using Cox proportional hazards models adjusted for potential confounders including HIV stage.
Results: There were 49,475 (74% women) HIV+ individuals who met inclusion and exclusion criteria. Mortality rates for
men and women were 3.8 and 1.8/100 person-years, respectively, and highest among those with the lowest blood
pressures. Low blood pressure was associated with the highest mortality incidence rate (IR) (systolic <100 mmHg IR 5.2
[4.8-5.7]; diastolic <60 mmHg IR 9.2 [8.3-10.2]). Mortality rate among men with high systolic blood pressure without
advanced HIV (3.0, 95% CI: 1.6-5.5) was higher than men with normal systolic blood pressure (1.1, 95% CI: 0.7-1.7). In
weighted proportional hazards regression models, men without advanced HIV disease and systolic blood
pressure ≥140 mmHg carried a higher mortality risk than normotensive men (HR: 2.39, 95% CI: 0.94-6.08).
Conclusions: Although there has been little attention paid to high blood pressure among HIV+ Africans, we show
that blood pressure level among HIV+ patients in Kenya is related to mortality. Low blood pressure carries the
highest mortality risk. High systolic blood pressure is associated with mortality among patients whose disease is
not advanced. Further investigation is needed into the cause of death for such patients.
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Background
In North America and Europe, cardiovascular disease is
the second most common cause of death among HIV
seropositive (+) individuals after acquired immunodefi-
ciency syndrome (AIDS)-related mortality [1]. This trend
has been accompanied by a shift in the long-term care
of HIV+ patients to include attention to cardiovascular
risk [2,3]. Observational studies from around the globe
support the association between HIV infection and in-
creased risk of cardiovascular disease, however, these
studies have largely not included patients from develop-
ing countries [4-7].
Most people with human immunodeficiency virus (HIV)
infection live in sub-Saharan Africa (SSA). Sixty-nine per-
cent (23.5 million of 34 million) of all people infected with
HIV worldwide and the majority of HIV-related deaths are
in SSA [8]. Infectious and immunological factors have
usually been associated with the highest risk of death in
people living with HIV in SSA [9,10]. However, HIV+
individuals without AIDS in SSA can now achieve a
near normal life expectancy and hypertension is not
uncommon [11,12]. The degree to which high blood
pressure is related to mortality in HIV+ patients in the
region has not been specifically addressed [10]. This
may be related to under-recognition of the magnitude
of the risk of death associated with cardiovascular risk
factors among HIV+ individuals in SSA.
The relationship between blood pressure level and
mortality in HIV+ patients may have important policy
implications as HIV+ individuals age and programs in
SSA expand their scope to address the important overlap
between communicable and non-communicable diseases
[13]. Therefore, the aim of this study was to describe the
relationship between HIV infection, blood pressure level,
and death in a cohort of HIV+ adults without AIDS
from a large HIV treatment program in western Kenya.
By so doing, our objective was to describe the overall
relationship and identify important mortality differences
according to gender and clinical stage of HIV.
Methods
Ethics statement
This was a retrospective analysis of de-identified elec-
tronic medical records. Individual informed consent
was not obtained. The Institutional Research and Ethics
Committee of the Moi University School of Medicine
and the Institutional Review Boards of Indiana, Duke,
and Brown Universities approved use of these data and
waiver of informed consent.
Study design and participants
This retrospective study used de-identified data from the
electronic medical records of HIV+ adult patients treated
in the Academic Model Providing Access to Healthcare
(AMPATH) program. The AMPATH program is a clinical
care program based on a collaboration between Moi
Teaching and Referral Hospital, Moi University School of
Medicine and a consortium of North American univer-
sities. To date, AMPATH provides HIV care and treat-
ment to >150,000 adults and children living with HIV/
AIDS in over 50 clinics and satellite sites throughout
western Kenya. The AMPATH clinical care system was
created in 2001 and has been described in more detail
previously [14]. Clinic visits occurred monthly for all
patients on anti-retroviral therapy (ART) unless alterna-
tive arrangements were made with their health care pro-
vider. Patients who were not yet eligible for treatment
were seen monthly or bi-monthly depending on their
immunologic status and other factors in their health
profile. Standard paper data collection forms were used
at enrollment to the program and at each subsequent
visit. Data from these forms were entered into an elec-
tronic medical record by data entry technicians. A nurse
measured blood pressure during a clinical encounter
using a manual or digital sphygmomanometer. These
data were obtained for clinical care and were not rou-
tinely performed according to a protocol. Baseline blood
pressure was used for this analysis. Height and weight
were also measured as part of routine HIV care. Mortality
was assessed according to data available in the electronic
medical record and was statistically adjusted using a previ-
ously validated approach in the AMPATH program [15].
We included HIV+ patients aged 16 to 80 years who
were enrolled between January 1, 2005 and December
31, 2010 and who did not meet AIDS-defining criteria.
AIDS was defined by incorporating criteria from the
World Health Organization (WHO) [16] and Centers for
Disease Control [17] which include CD4 count less than
200/mm3, any AIDS defining illness, WHO Stage 4
disease, or a diagnosis of tuberculosis at the time of
enrollment or during follow-up. There were 92,586
adult patients who enrolled in the AMPATH program
during the specified time period. Of these, we ex-
cluded 41,249 who had a documented AIDS-defining
condition and another 25 who were younger than 16
or older than 80 at the time of enrollment. Another
1837 were excluded due to having data considered out
of acceptable range using the following criteria: systolic
blood pressure (SBP) <65 or >220 mmHg, diastolic
blood pressure (DBP) <40 or >120 mmHg, body mass
index (BMI) <15 or >40 kg/m2, and creatinine <8.84
or >884 mmol/L. There were 49,475 individuals eligible
and available for analysis (Figure 1).
Statistical analysis
The primary objective of our analyses is to characterize
the association between mortality and blood pressure at
enrollment. The first part of our analysis summarizes,
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for all individuals with available data, crude mortality
rates (deaths per 100 person years of observation) across
SBP (<100, 100-119, 120-139, ≥140 mmHg) and DBP
categories (<60, 60-79, 80-89, ≥90 mmHg), separately by
gender. In addition, we used proportional hazards regres-
sion models to characterize the conditional (adjusted)
effect of SBP and DBP on mortality, adjusting for base-
line demographic and clinical factors associated with
blood pressure, mortality, or both. The clinical factors
are CD4 cell count (200-350, >350), WHO Stage (1, 2 or 3),
BMI (<18.5, 18.5-25, 25-30, >30 kg/m2), hemoglobin
(in mg/dL), and serum creatinine level (in mmol/L).
Demographic factors are age (<35, 35-44, 45-54, ≥55 years),
sex, marital status (married or living with partner vs. not),
and clinic location (urban vs. rural). We subdivided the
sample according to those with advanced HIV disease,
defined as having CD4 < 350 or WHO Stage 2 or 3. The
adjusted effects of SBP and DBP are computed separ-
ately for each of the four strata defined by distinct com-
binations of gender and severity of HIV disease. We
fit a single model, using appropriately coded indicator
variables and interactions, to estimate the effects of SBP
and DBP on mortality within the four strata defined by
sex-HIV disease severity combinations. The adjustment
variables included in the model are assumed to have the
same effect across the strata. This assumption was
checked using Wald tests for interactions with gender
and HIV disease severity, none of which indicated evi-
dence for including interactions.
Handling missing covariate information
In the sample used for regression modeling, 30,224 of
49,475 individuals in the analysis sample had complete
information on all of the covariates listed above. To
address potential biases introduced by missing covariates,
we fit the model under different assumptions about the
relationship between mortality rate and having one or more
missing covariates. Specifically, we use an inverse prob-
ability weighting (IPW) method that, under certain assump-
tions detailed in Additional file 1 (Technical appendix),
corrects for potential biases attributable to differential sur-
vival distributions between those with and without missing
covariates [18]. The IPW method alleviates bias due to dif-
ferential survival between those with and without missing
covariates. The survival distributions between those with
fully observed and partially observed covariates was simi-
lar after applying the weighting, suggesting that a substan-
tial amount of selection bias is reduced in the weighted
sample, and supporting the use of IPW for fitting the pro-
portional hazards regression (see Additional file 1).
Results
Baseline descriptive characteristics are shown in Table 1.
Our population sample (n = 49,475) had more than 74%
Figure 1 Flow diagram of exclusion criteria to arrive at the final analysis profile. Legend: The records of all patients enrolled in the
Academic Model Providing Access to Healthcare program were screened for inclusion and exclusion criteria as described in the text. There
were 92,586 patients who were enrolled in the program between January 1, 2005 and December 31, 2010. We excluded patients sequentially
if they had an AIDS-defining condition, were <16 years, >80 years or had data that were out of acceptable range. Our final analysis sample
included 49,475 patients.
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Table 1 Summary of characteristics by gender
Variable Women (n = 36616) Men (n = 12859) Overall (n = 49475)
Age, median (IQR), years 32 (26-39) 38 (31-46) 33 (27-41)
Age category, No. (%), years
<25 7473 (20.4) 812 (6.3) 8285 (16.8)
25-34 15227 (41.6) 4183 (32.5) 19410 (39.2)
35-44 9049 (24.7) 4362 (33.9) 13411 (27.1)
45-54 3739 (10.2) 2447 (19.0) 6186 (12.5)
55-64 948 (2.6) 803 (6.2) 1751 (3.5)
≥65 180 (0.5) 252 (2.0) 432 (0.9)
SBP, median (IQR), mmHg 110 (100-120) 110 (100-120) 110 (100-120)
DBP, median (IQR), mmHg 70 (60-72) 70 (60-79) 70 (60-74)
SBP category, No. (%), mmHg
<100 3822 (10.4) 1083 (8.4) 4905 (9.9)
100-119 21145 (57.8) 6444 (50.1) 27589 (55.8)
120-139 10145 (27.7) 4488 (34.9) 14633 (29.6)
≥140 1504 (4.1) 844 (6.6) 2348 (4.8)
DBP category, No. (%), mmHg
<60 1748 (4.8) 571 (4.4) 2319 (4.7)
60-79 27702 (75.7) 9107 (70.8) 36809 (74.4)
80-89 5905 (16.1) 2620 (20.4) 8525 (17.2)
≥90 1261 (3.4) 561 (4.4) 1822 (3.7)
BMI, median (IQR), kg/m2a 21.5 (19.3-24.0) 20.1 (18.4-21.9) 21.0 (19.0-23.5)
BMI category, No. (%), kg/m2a
<18.5 5348 (16.8) 2855 (25.9) 8203 (19.1)
18.5 - <25 20645 (64.8) 7495 (67.9) 28140 (65.6)
25 - <30 4716 (14.8) 595 (5.4) 5311 (12.4)
≥30 1173 (3.7) 97 (0.9) 1270 (3.0)
Hemoglobin, median (IQR), g/dLb 11.8 (10.2-13.1) 13.8 (11.9-15.3) 12.2 (10.5-13.7)
Creatinine, median (IQR), μmol/Lc 60 (51-71.4) 76 (64.5-89) 63.8 (53-77)
CD4 count, median (IQR), cells/mm3d 413 (296-581) 363 (271-502) 399 (288-561)
CD4 category, no. (%), cells/mm3d
200-350 9705 (37.4) 4019 (46.8) 13,724 (39.8)
>350 16224 (62.6) 4566 (53.2) 20790 (60.2)
ART naïve at enrollment, No. (%) 33345 (91.1) 11645 (90.6) 44990 (90.9)
WHO stage at enrollment, No. (%)e
Stage 1 17304 (60.5) 4803 (48.0) 22107 (57.2)
Stage 2 6647 (23.2) 2658 (26.6) 9305 (24.1)
Stage 3 4666 (16.3) 2547 (25.5) 7213 (18.7)
Urban 16970 (46.4) 6165 (47.9) 23135 (46.8)
Married/living with partnerf 19045 (54.0) 9127 (73.1) 28172 (59.0)
Abbreviations: IQR interquartile range; SBP systolic blood pressure; DBP diastolic blood pressure; BMI body mass index; ART antiretroviral therapy; WHO, World
Health Organization. SI conversion factors: To convert hemoglobin to grams per liter, multiple by 10.
an = 31882 for women; 11042 for men.
bn = 26,826 for women; 9099 for men.
cn = 25,570 for women; 8799 for men.
dn = 25,929 for women; 8585 for men.
en = 28617 for women; 10008 for men.
fn = 47745.
Bloomfield et al. BMC Infectious Diseases 2014, 14:284 Page 4 of 10
http://www.biomedcentral.com/1471-2334/14/284
women. Although no one in the sample had AIDS, the
HIV disease burden was still substantial, with 47% of
men and 37% of women having a CD4 cell count below
350, and 25% of men and 16% of women having WHO
Stage 3 disease. Twenty-six percent of men and 17% of
women had a BMI less than 18.5 kg/m2. Nearly all indi-
viduals were ART naïve at the time of enrollment (91%),
however, the majority were prescribed ART at some
point during the observed follow up period. With regard
to specific antiretroviral agents, the most common regi-
men consisted of a non-nucleoside reverse transcriptase
inhibitor plus two nucleoside reverse transcriptase inhib-
itors. Overall, 7819 (16%) were prescribed efavirenz and
19,134 (39%) were prescribed nevirapine. Protease inhibi-
tors were prescribed for 5773 (12%) of patients. Tenofovir
was used by 4047 (8%) patients and zidovudine by 15,178
(31%). Hemoglobin and creatinine were within the normal
range for most patients. Both SBP and DBP were found
to be in the normal range (110-119 and 60-79 mmHg,
respectively) for 39% of men and 46% of women. SBP ≥140
or DBP ≥90 mmHg was found in 10% of men and 7% of
women, respectively.
Among women, there were 1351 deaths in 75,786 per-
son years (py) of follow up (mortality rate 1.8/100 py).
Among men, there were 966 deaths in 25,369 py of
follow up (mortality rate 3.8/100 py). With respect to
blood pressure, within gender, crude mortality rates are
substantially higher for those in the lowest SBP and DBP
categories compared to all other categories. The differ-
ence is particularly pronounced among men, where mor-
tality rate is 10.7/100 py for those with SBP <100 and
16.4/100 py for those with DBP <60 mmHg.
Figure 2 shows age-adjusted survival curves stratified by
SBP and DBP categories, separately for each gender. The
curves depict expected survival probabilities when age is
fixed at 35 years demonstrating that those with low DBP
and SBP have the highest age adjusted mortality rates.
Additional files 2 and 3 (Figures S3 and S4) are smoothed
linear spline curves applied to the unweighted sample of
all individuals having baseline blood pressures showing
the relationship between blood pressure and mortality rate
among men and women with and without advanced HIV.
The unadjusted mortality rate was stratified according
to the presence of advanced HIV disease and blood
Figure 2 Adjusted survival curves by SBP and DBP categories, stratified by gender. Legend: Survival curves are adjusted for age (set to 35)
and stratified by systolic and diastolic blood pressure categories. SBP: systolic blood pressure. DBP: diastolic blood pressure.
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pressure in women and men (Table 2). The highest mor-
tality rates were seen in those with the lowest SBP and
DBP (systolic <100 mmHg 5.2/100 py [4.8-5.7]; diastolic
<60 mmHg IR 9.2/100 py [8.3-10.2]). Patients with the
lowest systolic and diastolic blood pressures also had
lowest CD4 counts, body mass index and hemoglobin
as shown in (Additional file 4: Table S4). In addition,
the death rate among men without advanced disease
and with SBP ≥140 mmHg (3.0, 95% CI: 1.6-5.5) was
nearly three-fold greater than those with normal SBP
(1.1, 95% CI: 0.7-1.7). This observation was not present
among women or among those with advanced HIV dis-
ease. There was a similar relationship to high DBP such
that high DBP in men without advanced HIV (2.9, 95%
CI: 1.5-5.9) was associated with a higher death rate than
those with normal DBP (1.7, 95% CI: 1.3-2.2).
Table 3 shows results from the weighted proportional
hazards regression model. For both men and women,
SBP <100 or DBP <60 mmHg had greater mortality risk
relative to those in the normotensive reference range. The
effect of low DBP was most pronounced among those
with more advanced HIV disease, with hazard ratio
(HR) 2.76 (95% CI: 1.98-3.83) among women and 3.19
(95% CI: 2.14-4.74) among men. Both SBP 120-139 (HR:
1.91, 95% CI: 1.01-3.59) and ≥140 mmHg (HR: 2.39,
95% CI: 0.94-6.08) carry higher mortality risks among
men whose HIV disease is not advanced relative to nor-
motensives. This relationship was not observed among
men with advanced HIV disease. High DBP was not
associated with a greater risk of death. Low BMI, older
age, higher creatinine, lower hemoglobin, an urban
clinic setting, and not being married were all associated
with greater risk of death regardless of HIV disease
stage. Table 3 also demonstrates that the mortality risks
associated with high blood pressure were generally
smaller among patients with advanced HIV disease. We
did not undertake significance testing of every pairwise
comparison. In a separate analysis, the interaction
between blood pressure level and HIV disease stage was
found to be statistically significant for women (p < 0.001),
and separately for men (p < 0.001).
Discussion and conclusions
Chronic, non-HIV related conditions are an increasingly
important part of HIV management, a trend that has his-
torically been underappreciated [19]. While the burden of
Table 2 Unadjusted mortality rates per 100 person years by blood pressure groups for men and women with and
without advanced HIV
Characteristic Person years Women events Mortality rate (95% CI) Person years Men events Mortality rate (95% CI)
Advanced HIVa
Systolic blood pressure
SBP <100 mmHg 3447 113 3.3 (2.7-3.9) 816 57 7.0 (5.4-9.1)
SBP 100-119 mmHg 18648 364 2.0 (1.8-2.2) 5966 219 3.7 (3.2-4.2)
SBP 120-139 mmHg 7954 116 1.5 (1.2-1.7) 4001 96 2.4 (2.0-2.9)
SBP ≥140 mmHg 1095 23 2.1 (1.4-3.2) 590 21 3.6 (2.3-5.5)
Diastolic blood pressure
DBP <60 mmHg 1164 73 6.3 (5.0-8.0) 356 56 15.8 (12.1-20.5)
DBP 60-79 mmHg 23988 467 1.9 (1.8-2.1) 8142 283 3.5 (3.1-3.9)
DBP 80-89 mmHg 4913 58 1.2 (0.9-1.5) 2372 45 1.9 (1.4-2.5)
DBP ≥90 mmHg 1079 18 1.7 (1.1-2.6) 504 9 1.8 (0.9-3.4)
Not advanced HIV
Systolic blood pressure
SBP <100 mmHg 1707 28 1.6 (1.1-2.4) 221 9 4.1 (2.1-7.8)
SBP 100-119 mmHg 12625 91 0.7 (0.6-0.9) 2097 23 1.1 (0.7-1.7)
SBP 120-139 mmHg 6461 38 0.6 (0.4-0.8) 1906 34 1.8 (1.3-2.5)
SBP ≥140 mmHg 842 8 0.9 (0.5-1.9) 339 10 3.0 (1.6-5.5)
Diastolic blood pressure
DBP <60 mmHg 824 21 2.5 (1.7-3.9) 89 2 2.2 (0.6-9.0)
DBP 60-79 mmHg 16301 121 0.7 (0.6-0.9) 3195 54 1.7 (1.3-2.2)
DBP 80-89 mmHg 3766 20 0.5 (0.3-0.8) 1006 12 1.2 (0.7-2.1)
DBP ≥90 mmHg 744 3 0.4 (0.1-1.3) 272 8 2.9 (1.5-5.9)
Abbreviations: HIV human immunodeficiency virus, SBP systolic blood pressure, DBP diastolic blood pressure.
aAdvanced HIV is defined by CD4 count <350, or WHO Stage 2 or 3.
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high blood pressure among Africans living with HIV has
been highlighted, the impact of blood pressure on import-
ant clinical endpoints has not been well established and
therefore has not routinely been a focus of treatment in
HIV programs in the region [12,20]. With this gap in the
literature in mind, we have shown that low enrollment
SBP or DBP is associated with a high mortality risk among
HIV+ patients. There was also a relationship between
higher initial SBP and mortality in men without advanced
HIV. In adjusted analyses, the effect of high blood pres-
sure was smaller than the effect of low blood pressure.
The greatest mortality risks in the present analysis were
related to low blood pressure. In addition to advanced dis-
ease stage, other well-documented reasons for low blood
pressure in HIV+ patients include adrenal insufficiency,
autonomic dysfunction, concomitant infections, and the
effects of bacterial translocation among others [21-23].
The cause of low blood pressure was not identifiable in
this study, however, these factors as well as concomitant
illness may have contributed to the observed low blood
pressure. Lower blood pressure has also been observed in
patients with more advanced HIV disease [24] and we
posit this explanation in this analysis based on the de-
ranged parameters of body mass index, hemoglobin and
CD4 count in those with the lowest blood pressure. The
mortality risk, however, was large and indicates the need
to explore concomitant clinical factors as well as cause of
death in this population. Such data and relatively simple
measures such as blood pressure measurement are only
recently beginning to be explored in HIV cohorts on the
continent, highlighting a strength and relevance of this
analysis [25].
Table 3 Mortality hazard ratios from proportional hazards regression models using inverse probability weighting for
missing covariates
Variable Women Men
Advanced HIVa Advanced HIV
Yes No Yes No
SBP, mmHg
<100 1.28 (0.98-1.68) 2.29 (1.37-3.80) 1.61 (1.09-2.39) 2.95 (1.17-7.44)
100-119 ref ref ref ref
120-139 0.83 (0.64-1.07) 0.94 (0.60-1.47) 0.73 (0.53-1.00) 1.91 (1.01-3.59)
≥140 0.97 (0.58-1.60) 1.06 (0.47-2.41) 1.24 (0.74-2.08) 2.39 (0.94-6.08)
DBP, mmHg
<60 2.76 (1.98-3.83) 2.26 (1.19-4.26) 3.19 (2.14-4.74) 1.88 (0.45-7.78)
60-79 ref ref ref ref
80-89 0.65 (0.47-0.90) 0.67 (0.37-1.22) 0.68 (0.47-0.98) 0.92 (0.46-1.84)
≥90 1.15 (0.62-2.14) 0.57 (0.19-1.71) 0.66 (0.28-1.56) 1.65 (0.61-4.47)
BMI, kg/m2b
<18.5 1.82 (1.55-2.13)
18.5 - <25 ref







Log creatinine 1.28 (1.04-1.58)
Hemoglobin, g/dL 0.81 (0.79-0.83)
ART naïve 0.99 (0.67-1.45)
Urban clinic 0.84 (0.73-0.98)
Married 0.73 (0.64-0.85)
Abbreviations: SBP systolic blood pressure, BMI body mass index, ART anti-retroviral therapy.
aAdvanced HIV is defined as CD4 < 350, or WHO Stage 2 or 3.
bHazard ratios for BMI, Age, log creatinine, hemoglobin, ART naïve, urban clinic and married apply to all 4 strata.
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Western literature supports a relationship between
higher SBP and mortality in HIV+ men. In the Multicen-
ter AIDS Cohort, Seaberg et al., demonstrated that the
prevalence of systolic hypertension among men taking
ART for less than two years was similar to that of HIV
seronegative (-) men, but was nearly two-fold higher
after two to five years of ART and five years or more of
ART [26]. Other studies support the relationship be-
tween HIV positivity and higher blood pressure, but this
is still debated [27-29]. Compared to Western countries,
there has been relatively little attention paid to the over-
lap between non-communicable cardiovascular diseases
and HIV in SSA. In a large systematic review and meta-
analysis (50 studies including 38 from SSA) of early
mortality in adults initiating ART in low- and middle-
income countries, blood pressure was not reported as a
covariate of interest in any of the studies [10].
Data from the SSA region regarding blood pressure,
however, are slowly emerging. The overall rate of hyper-
tension among HIV+ patients in SSA is estimated to be
8-19%, and slightly higher among men compared to
women [12]. In Kenya, a program showed that when
people are screened for HIV and non-communicable
diseases simultaneously, HIV+ people had higher rates of
hypertension (32%) than those who were HIV- (19%) [30].
Similar findings are reported from Tanzania, Botswana,
and Nigeria while in our analysis hypertension was present
in less than 10% of the population [31-33]. A systematic
review and meta-analysis of the association between HIV
and cardiometabolic traits, however, suggests that HIV+
patients have, on average, lower blood pressure than their
HIV- counterparts [34]. It is noteworthy that the studies
included in this review vary in patient population, method
of screening, selection of patients and definitions of out-
comes resulting in an unresolved relationship between
blood pressure and HIV. Given the size of our HIV care
program, we believe the observed relationship between
high blood pressure and mortality may be generalizable
to the region, however, country-specific data comparing
HIV+ to HIV- patients are needed to put the magnitude
of the issue in a relevant context. Both high and low
blood pressure impact mortality in these patients sug-
gesting that addressing blood pressure in HIV+ patients
in SSA is potentially a lost opportunity to modify health
and impact mortality.
The differences in mortality risk between men and
women warrant further exploration. The reasons for the
observed higher mortality risk related to high blood pres-
sure among men compared to women may be related to a
true sex-related difference in the impact of high blood
pressure or reflect other factors that vary according to
sex including less health-seeking behavior among men
or higher burden of other cardiovascular risk factors
(e.g., tobacco smoking) among men [35]. Moreover,
most of the women in this analysis were of pre-menopausal
age and may therefore carry lower risk of cardiovascular
disease than men. Prospective analyses that can control
for known sex-based differences will be able to eluci-
date whether higher blood pressure among HIV+ men
carries a greater mortality risk than among women.
Some limitations of our study should be considered.
This was a retrospective analysis of clinical data and
variables, including blood pressure, that were not mea-
sured routinely in every patient or in a standard,
protocol-driven manner. Our analysis is therefore lim-
ited by a selection bias potentially introduced at the
time of the clinical encounter and our observations do
not confirm causality. We had a significant proportion
of patients missing data and while this is often the situ-
ation in reality, we addressed this by using IPW to
account for differences in mortality between those with
and without missing covariates. Our weighting approach
resulted in similar survival distributions between those
with fully observed and partially observed covariates and
supported its use for fitting the proportional hazards
models. Incomplete data is not uncommon in HIV
treatment programs in SSA and our approach repre-
sents one method for addressing this phenomenon [11].
Information on diabetes, smoking or use of cardio-
vascular medications was also not routinely measured
during this time. Further, cause of death information
was not available for this cohort and we are therefore
limited in our ability to comment on the mechanism
of the association between BP and mortality in this
analysis. Given than non-communicable cardiovascular
causes of death present at a younger age in populations
earlier in the epidemiologic transition, it seems necessary
to investigate these associations as well as possible mecha-
nisms in HIV+ patients. Data from the region using verbal
autopsy, however, show that non-communicable diseases
account for between 2 and 10% of deaths among HIV+
individuals on ART [36,37].
In summary, while cardiovascular risk factor levels
remain low in SSA in general and life expectancy among
HIV+ individuals nears 80% of normal, a rare opportunity
currently exists to understand and decrease or prevent
cardiovascular risk in a population still on the cusp of a
non-communicable disease epidemic. Literature from
developed countries support a relationship between
HIV and cardiovascular disease risk and the burden of
HIV in SSA calls for more attention to these comorbidi-
ties. Using clinical data from a large HIV treatment pro-
gram in western Kenya, we have demonstrated that low
and high blood pressures in HIV+ patients are important
predictors of mortality with low blood pressure carrying
the greatest mortality risk. Of particular clinical relevance
is the finding that high blood pressure is associated with
higher mortality risk among patients whose HIV disease is
Bloomfield et al. BMC Infectious Diseases 2014, 14:284 Page 8 of 10
http://www.biomedcentral.com/1471-2334/14/284
not advanced. Therapy for high blood pressure should
be instituted when indicated. Patients with low blood
pressure should undergo a thorough assessment to un-
cover and reverse the causes. To our knowledge, this is
one of the first and largest reports from the region indi-
cating this relationship and highlights the need to address
cardiovascular diseases in this population, especially
among patients without advanced HIV. Programs in
SSA that are narrowly focused on HIV treatment alone
may be missing an important opportunity to modify
health.
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appendix. The supporting technical methodological appendix includes
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Additional file 1 includes Tables S1, S2 and S3; and Figures S1 and S2.
Additional file 2: Figure S3. The panels in Figure S3 are smoothed
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